ReviewDrugs2025
Tuberculosis Preventive Treatment in High TB-Burden Settings: A State-of-the-Art Review.
Review in Drugs, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Shorter Antitubercular Regimens Versus 9 Months of Isoniazid for Latent Tuberculosis in Children: A Systematic Review and Meta-Analysis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Pooled it
- Psychosocial interventions to improve tuberculosis preventive treatment uptake and psychosocial outcomes: a systematic review.NPJ primary care respiratory medicine · 2025Pooled it
- Trial
- Article
- Diagnostic value of nanopore-based targeted sequencing technology for subclinical tuberculosis.BMC microbiology · 2026Article
- Effect of prior TB preventive therapy on all-cause mortality during TB treatment among people with HIV/TB in rural eastern Uganda: an observational causal analysis.BMC infectious diseases · 2026Observational
- Commentary: Nurses at the frontline of the Tuberculosis epidemic-strengthening care in patients across health settings.Journal of research in nursing : JRN · 2026Article
- Review
- Tuberculosis in Pregnancy: An Updated Narrative Review.Diagnostics (Basel, Switzerland) · 2026Review
- Article
- Article
- Tuberculosis prevention in children, adolescents, and pregnant and postpartum women in South Africa.South African family practice : official journal of the South African Academy of Family Practice/Primary Care · 2026Article
- Prognostic significance of inflammatory and nutritional indicators for treatment outcomes in untreated tuberculosis patients with hypertension.Frontiers in nutrition · 2026Article
- Scaling-up tuberculosis preventive therapy to HIV-negative contacts of bacteriologically confirmed TB cases aged 5 years and above - Lessons from a tuberculosis preventive therapy surge activity in Zambia.PLOS global public health · 2026Article
- How do social network models compare to all-to-all models for forecasting tuberculosis epidemics? A mathematical modeling study.PloS one · 2026Article
- Leadership and political will are needed to address tuberculosis in Canada.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2025Article
- New drugs for the management of tuberculosis.Current opinion in infectious diseases · 2025Review
- Optimising child-friendly TB preventive treatment regimens.IJTLD open · 2025Article
- Prevalence and Risk Factors of Latent Tuberculosis Infection Detected by IGRA in Patients with Immune-Mediated Inflammatory Diseases Before and During Biologic DMARD Therapy (TITAN Study).Journal of clinical medicine · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Tuberculosis (TB) is the leading cause of death from a single infectious agent. The burden is highest in some low- and middle-income countries. One-quarter of the world's population is estimated to have been infected with TB, which is the seedbed for progressing from TB infection to the deadly and contagious disease itself. Although some individuals may clear their infections through innate and acquired immunity, many do not. People living with HIV, TB-exposed household contacts, other individuals recently infected, and immunosuppressed individuals are at especially high risk of progressing to TB disease. There have been major advances in recent years to support the programmatic management of TB infection. New tests of infection, including those that predict progression to TB disease, have become available. Numerous World Health Organization-recommended TB preventive treatment (TPT) regimens are available for all ages and for both drug-susceptible and drug-resistant TB infection. All regimens are generally safe, efficacious, and cost effective and have a low risk of generating resistance. TPT is recommended for pregnant women who are at risk for developing TB, but some regimens are associated with an increased likelihood of poor obstetric and fetal outcomes, and newer regimens have not yet been tested in pregnancy. New formulations of rifapentine-based TPT have been developed, and the cost has been radically reduced. Innovative models of delivery to support the scale up of TPT have been developed. Modeling suggests that scaling up TPT, especially regimens with optimal target product profile characteristics, can contribute substantially to ending the TB epidemic. The global uptake of TPT has increased substantially, especially for people living with HIV. Implementation gaps remain, particularly for children, pregnant women, and other household contacts. Further innovation is required to support the continued scale up of TPT and to contribute to ending the TB epidemic.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.